The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Lisata Therapeutics. This endorsement reaffirms the firm's confidence in the company's potential, likely encouraging both current and potential investors about the stock's future performance.